Private or NHS weight management: where does a pharmacy clinic fit now?

Where does the NHS rollout stand?

Well behind demand, and uneven. NICE recommended tirzepatide in December 2024, and NHS England's interim commissioning guidance, updated on 2 April 2026, phases access in primary care over three years. Year one, from 2025/26, covers people with a BMI of 40 or more and at least four qualifying conditions: hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. Year two widens that to a BMI of 35 to 39.9 with four conditions, and year three to a BMI of 40 with three. Thresholds drop by 2.5 for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background.

The numbers tell the story. NHS England estimates 3.4 million people meet the full NICE criteria. The phased programme plans for about 220,000 over its first three years. Semaglutide, under TA875, stays inside specialist weight-management services with a two-year limit, and The Pharmaceutical Journal's July 2026 briefing put access to those services at about 1% of eligible patients.

Inside those phases, ICBs are rationing. The Pharmacist's analysis on 2 March 2026 found Greater Manchester had split cohort one into three sub-cohorts to prioritise the sickest. Humber and North Yorkshire added exclusions for unstable mental illness, recent bariatric surgery and eating disorders. Lancashire and South Cumbria limited access to its most deprived areas. South Yorkshire will require a supported weight-loss attempt in the previous 24 months before it considers a drug. Among the ICBs examined, uptake ranged from 895 patients in North East and North Cumbria, 2.77 per 10,000 people, to 68 in North East London, 0.28 per 10,000. The national expectation is 37 per 10,000.

The one new NHS commitment is a pilot fund, not a service. On 27 June 2026 the government announced an £85 million Obesity Pathway Innovation Programme: up to £50 million from government and up to £35 million from Lilly. Its projects include six neighbourhood hubs in community pharmacies and gyms across Leicester, Leicestershire and Rutland, and pharmacy-based obesity care in south London with online and in-person options. That is the first time NHS money has been attached to pharmacy-delivered obesity care, and it is a test.

Who is left for a private clinic?

Almost everyone. A UCL survey study in BMC Medicine, reported on 8 January 2026, estimated 1.6 million adults in Great Britain used a weight-loss drug in the year to March 2025. A further 3.3 million were interested. Set that against 220,000 NHS places over three years and the arithmetic is simple. The private market is not the overflow from the NHS; the NHS is the exception inside a private market.

Three groups walk into a pharmacy clinic. The first is eligible but waiting: a BMI of 36 with three conditions, or a BMI of 42 whose ICB has added an exclusion. The second is licensed but not NHS: the Mounjaro and Wegovy licences start at a BMI of 30, or 27 with a weight-related condition, well below the NHS threshold of 35. The third is the returner. Data presented at the Endocrine Society's meeting on 14 June 2026 covered 60,000 US patients with type 2 diabetes. 40% stopped a GLP-1 within a year, and 42% of those restarted within a year. Treatment is start-and-stop, and each restart is a new consultation.

The launch of oral semaglutide changes the size of the second group. The MHRA authorised the Wegovy tablet on 11 June 2026 for adults with a BMI of 30 or more, or 27 with a comorbidity. Doses escalate from 1.5 mg to 25 mg daily. It launched on 6 July 2026 through private weight-management programmes only; NICE has not appraised it for the NHS. An NPA survey of 310 owners, reported on 6 July 2026, found 76% expected to treat significant numbers of patients with it and 49% had already seen more enquiries. Our analysis of what the Wegovy pill means for pharmacy covers the operational side.

What must a private clinic verify?

The same things an NHS prescriber can see on the record, and you have to go and get them. The GPhC's February 2025 guidance on services at a distance puts medicines for weight management in the category needing extra safeguards. The prescriber must independently verify the person's weight, height or BMI, by video, in person, from clinical records or by contacting another provider such as the GP. The guidance says in terms that a phone call is not appropriate for weight-loss medicines. The prescriber must also verify the medical history, normally by contacting the GP or regular prescriber with consent. Monitoring arrangements must be in place before prescribing.

The GPhC's updated inspection framework of 13 January 2026 tells inspectors to test those points, so a questionnaire-only model now fails inspection rather than merely attracting criticism. Our summary of the verification duties lists what inspectors ask for. The regulators have also been explicit about promotion. On 18 June 2026 the MHRA, ASA and GPhC jointly warned against advertising the new oral GLP-1s or unlicensed pipeline products. On 7 July 2026 the MHRA named Tesco Pharmacy among 18 companies that had corrected weight-loss advertising in 2026. Advertise the service, never the medicine, as set out in our guide to weight-loss advertising.

Who regulates you depends on who prescribes. A pharmacist independent prescriber working in a registered pharmacy is regulated by the GPhC. A clinic in which a doctor prescribes for weight reduction is carrying out a CQC-regulated activity. Schedule 1 to the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 lists services in a slimming clinic. That covers the prescribing of medicines for weight reduction by or under the supervision of a medical practitioner. Clinic-plus-pharmacy operators need both registrations lined up; see how the CQC regulates online clinics.

How NHS and private monitoring differ

On paper, hardly at all; in funding, completely. NHS England's wraparound-care guidance of 5 January 2026 describes what an NHS patient gets. There are monthly titration and monitoring appointments with the prescriber and a behavioural support programme delivered over nine consecutive months. Stopping is a shared decision on when and how. NICE NG246 sets a checkpoint at six months on the highest tolerated dose: if less than 5% of starting weight has gone, the prescriber decides whether to continue. NICE quality standard QS212, published on 5 August 2025, adds statement 6 on wraparound care alongside the medicine and statement 7 on at least a year of feedback and monitoring after stopping.

A private clinic is not held to a lower standard because the patient pays. The GPhC assesses it against the same NICE guidance, and the prescriber's duty to decide what monitoring follows each prescribing decision is in the GPhC's April 2025 guidance for pharmacist prescribers. The practical difference is that the NHS has a funded nine-month programme and monthly appointments already, while you must build them into the price. The pharmacies in trouble are the ones that priced the pen and gave the reviews away, then stopped doing them. Our guide to what monitoring weight-loss patients need sets out a schedule that survives inspection.

How should you price it?

Price the clinical work, and let the medicine be what it costs. Since 1 September 2025 Lilly's list prices for Mounjaro have been £133 for the 2.5 mg pen and £330 for 12.5 mg and 15 mg. The old range was £92 to £122. Lilly offered rebates to pharmacies and some operators froze their retail prices, but the drug now dominates the patient's monthly bill and leaves little margin. A clinic that competes on pen price is competing with the largest online operators on their terms.

The alternative is a fee for each thing NICE says should happen. A verified initial assessment, including GP contact and bloods where indicated. A review at each dose step. A six-month continuation review against the 5% threshold. A maintenance programme after stopping, which few pharmacies sell and NICE already specifies. Publish the fees for those, show the medicine as a pass-through cost, and you have a price list a patient can compare honestly and a regulator cannot object to.

Two things to avoid. Do not bundle three or six months of pens into a discounted package. The stockpiling ahead of the 2025 price rise drew warnings from the Royal Pharmaceutical Society and the NPA. A bundle also locks a patient into a dose before you know they tolerate it. And do not put the medicine, its name or its price in any public-facing advertising. The MHRA's June 2026 warning covered terms such as "GLP-1 tablets" and "oral GLP-1s". Its July action against Tesco covered indirect references to weight-loss injections that would lead a member of the public to ask for a prescription-only medicine.

Should you wait for an NHS service?

No, because there is nothing to wait for yet. The 2026/27 contract settlement announced on 29 May 2026 funds an NHS independent prescribing service from autumn 2026. Its scope is prescribing within Pharmacy First, the contraception service and supply-chain alternatives, plus up to five prescribing-only Pharmacy First pathways. Weight management is not in it. What the sector has instead is an argument and a pilot. On 25 March 2026 Boots's superintendent pharmacist told the Health and Social Care Committee that community pharmacy is "perfectly placed" to deliver a nationally commissioned weight-management service. In June came the £85 million pilot programme.

The pilots are the thing to watch, and they are selective. The projects run through ICBs and NHS boards with partners including the Health Innovation Network. The Leicester hubs and the south London pharmacy pathway are pilots, and pilots report before anyone commissions at scale. The pharmacies inside them are ones that already run weight-management services with the governance to show for it. Waiting for a national specification means arriving at that moment with no data and no patients.

The sensible reading is that a private clinic is the route into any future NHS work, not an alternative to it. Build it to the NHS pathway's shape: verified baseline, monthly reviews during titration, a behavioural offer, a six-month checkpoint and a maintenance plan. If a commissioned service follows, you have the workflow and the outcome data. If it does not, you have a clinic that meets QS212 and is paid for by the people using it. Our guide to setting up a weight-management clinic covers the build.

How to position the clinic

As the clinically serious option, priced openly. The market has two poles. At one end are the largest online operators, competing on pen price and speed, and under sustained regulatory attention for it. At the other is the illegal market. The MHRA seized more than 5,000 GLP-1 units among £45 million of illegal medicines in 2025. On 24 July 2026 it warned again that there is no summer shortcut to safe weight loss. A pharmacy clinic sits between them, and its pitch is that a patient can be seen, measured, reviewed and followed up by someone who is accountable.

Positioning against the NHS is not the point. A GP who cannot offer tirzepatide to a patient with a BMI of 36 needs somewhere safe to send them. A patient who came off NHS treatment under the two-year semaglutide limit needs maintenance. A clinic that sends the GP a summary after every assessment, and that refers back when a patient becomes NHS-eligible, gets referrals in both directions. The pharmacies doing this well treat the NHS as a partner they are ahead of, not a competitor they are waiting for.

Key takeaways

FAQs